A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

This study is looking for women who have advanced ovarian cancer, or similar cancers of the fallopian tube or peritoneum, that has been confirmed by a doctor. You would need to have already had surgery and completed your first course of chemotherapy, and your cancer should have responded well to that treatment – meaning it’s stable, partly gone, completely gone, or not detectable.

There are also some important health checks. For example, if you have HIV, it needs to be well-controlled. Similar rules apply if you have hepatitis B or C – these conditions need to be managed and not active. You would also need to provide a sample of your tumor tissue that hasn't been treated with radiation before.

However, there are reasons why you might not be able to join. For instance, if your cancer is a very specific type (like certain low-grade or borderline tumors), or if you have cancer that has spread to your brain or spinal cord. Other health conditions like severe eye disease, active inflammatory bowel disease needing strong medication, or serious, uncontrolled heart or blood vessel problems would also prevent you from taking part. You also can’t have had systemic cancer treatment (other than your initial chemotherapy) or certain vaccinations recently, or another type of active cancer or serious infection.

If you decide to take part in this study, you would first go through a screening process to make sure the study is right for you. This might involve additional hospital visits, more tests, and discussions with the study team. Once enrolled, you would receive either the study medicine (sac-TMT, with or without bevacizumab) or standard care, which could be bevacizumab or observation, depending on which group you are assigned to. This is done by chance, like flipping a coin. You'll need regular appointments, usually at the clinic, for check-ups, blood tests, and to receive your treatment. Doctors will closely monitor your health and how your cancer is responding. The duration of your participation will vary depending on your treatment plan and how your body responds. The study team will explain the full schedule of visits and assessments to you in detail.